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OBJECTIVES: To compare the estimates of Prevalence Ratio (PR) and Odds Ratios
(OR) as effect measures in the analysis of cross sectional data for obese individuals
sufferingwith chronic comorbid conditions.METHODS:Medical Expenditure Panel
Survey data files from 2005-2007 was utilized for the analysis. Obese adults were
defined as individuals with age 20 years and having a BMI 30. Prevalence ratios
were estimated from logistic regressions by dividing predicted prevalence esti-
mates of comorbidities among obese individuals to the predicted prevalence of
comorbidities in non-obese individuals after adjusting for socio-demographic fac-
tors. Ninety-five percent boot-strapped confidence intervals were generated
around the prevalence ratios. Odds ratios were generated by using the ‘Survey
Logistic’ syntax in SAS after adjusting for the same socio-demographic factors.
RESULTS: Both odds ratios and prevalence ratios indicate that obese individuals
have a greater burden of chronic conditions in the United States. Obese individuals
had the greatest odds of having hypertension and osteoarthritis followed by coro-
nary heart disease, diabetes and dyslipidemia. Prevalence ratios were highest for
diabetes, followed by hypertension, osteoarthritis and dyslipidemia. Odds ratios
were almost always greater than the prevalence ratios for all chronic conditions.
The confidence intervals derived around odds ratios were also wider than the
confidence intervals around the prevalence ratios. CONCLUSIONS: The relative
importance of obesity upon different disease conditions differed depending on
whether PR or OR were estimated. This study along with previous literature shows
that odds ratiosmay be overestimating the true effect of a disease condition on the
prevalence of a comorbid disease. Although it is easier to derive odds ratios, prev-
alence ratiosmay bemore realistic estimates of the true public health burden. Thus
prevalence ratios should ideally be used as effect measures instead of odds ratios
especially for commonly occurring disease conditions.
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TREATMENT OF CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS)
KNOWLEDGE STUDY (TOCKS): NOVEL DATA COLLECTION, VIEWING AND
DYNAMIC REPORTING MECHANISM
Arnold RJ1, Groesser K2
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New York, NY, USA
OBJECTIVES:The objective of knowledge study (TOCKS)was to quantify the patient
burden and to characterize patient symptomatology and acceptance of treatment
with anakinra in Cryopyrin-associated Periodic Syndrome (CAPS), an orphan dis-
ease. Additionally, chart review and patient recall of symptoms, adverse events,
and resource use were compared. The aforementioned objectives were completed
through the use of a unique online approach to gathering data and rapidly display-
ing the results.METHODS: This retrospectivemedical chart review and concurrent
online patient survey, conducted in Centers of Excellence for CAPS in Europe, was
accomplished by analyzing data entered via internet-based case report forms
(CRFs). Data were entered into the CRFs by both study groups for two distinct
collection periods—prior to and during the most recent 12 months of anakinra
treatment. RESULTS: Four sites (50 patients total) participated in TOCKS. Prior to
entering data, users viewed an online tutorial to help in completing the survey. No
patients were lost to follow up and the data were successfully collected, analyzed,
and reviewed via the online CRF and dynamically-generated data tables. This in-
novative online approach allowed users to enter de-identified data, in multiple
sessions, even in the most remote destinations. One patient successfully com-
pleted their survey in the Amazon. In addition, a unique identifier was randomly
generated that linked chart review with patient recall data online. Site investiga-
tors were also able to view the dynamic tables and reports online and benchmark
themselves against the other, encrypted, sites. CONCLUSIONS: This novel internet
technology allowed for efficient data collection from multiple sites and multiple
sources within a short time frame. The unique identifier made it effortless to col-
lect and compare the entries from the chart and from the patients for the same
patient.
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OBJECTIVES: To compare rates of obesity-associated comorbidities between the
General Electric (GE) Centricity EMR and Thomson Reuters MedStat MarketScan
commercial claims databases in patients with either a recorded BMI 25 (GE EMR)
or ICD-9 code for overweight/obesity (MarketScan). METHODS: From the GE EMR,
subjects aged 20-64 with at least one BMI value 25 and 2 y of EMR activity prior
to BMI index date were included. FromMarketScan, subjects 20 y (mostly 65 y),
with a claim (ICD-9 code) for overweight, obesity, ormorbid obesity, and365 days
of claims activity after selected comorbidity was first recorded, were included.
Selected comorbidities were identified by ICD-9 codes in both databases and strat-
ified by BMI or overweight/obesity claims. RESULTS: In the GE EMR, 109,885 sub-
jects (36.7%) were overweight or obese (BMI 25). Of these, 51% had BMI 25-29.9,
28% had BMI 30-34.9, and 22% had BMI 35. In the MarketScan database, 246,261
subjects (0.7%) had overweight, obesity, ormorbid obesity claims. Of these, 4%were
overweight, 66% were obese, and 30% were morbidly obese. The three most prev-
alent comorbidities in both databases, across all weight categories, were hyperten-
sion, hyperlipidemia, and chronic back pain, except diabetes replaced back pain in
the morbid obesity group in MarketScan. For all comorbidities, prevalence was
higher in MarketScan, except polycystic ovary syndrome prevalence was higher in
GE EMR BMI 35 group compared to morbid obesity group in MarketScan.
CONCLUSIONS: Despite different methods (BMI vs. ICD-9 codes) for capturing obe-
sity between two databases, prevalence rankings of comorbidities were similar.
Obesity is therapeutically classified by BMI; however, most large claims databases
capture obesity by ICD-9 codes. This may result in variation in weight group dis-
tributions and significant under-reporting of obesity claims in MarketScan. Our
findings highlight the need for further research in optimal sources for data in obese
patients.
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ESTIMATING THE BMI-MORTALITY RELATION USING FRACTIONAL
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OBJECTIVES: This study tests a flexible modeling approach, which endogenously
estimates the non-linear and asymmetric functional form for body mass index
(BMI), to examine the relationship betweenmortality and obesitymeasured as BMI
30. METHODS: This study used the National Health Interview Survey (NHIS),
between 1997 and 2000. Respondents were linked to the National Death Index with
mortality follow-up through 2005. We estimated the 5-year probability of death
using the logistic regression model adjusting for BMI, age and sex. The multivari-
able fractional polynomials (MFP) procedure was employed to determine the best
fitting functional form for BMI and compared to alternative functional forms using
a chi-squared test. Expected years of life lost due to obesity were based on adjusted
death probabilites and computed using standard life table functions.RESULTS:The
best fitting adjustment model contains the powers 1 and 2 for BMI. A chi-
squared test shows a statistically significant improvement in model fit compared
to other BMI polynomial functions. The estimated relationship between 5-year
probability of death and BMI exhibits a J-shaped pattern forwomen and aU-shaped
pattern for men. The BMI associated with minimum mortality is 27.53 for males
and 25.19 for females. A 40-year-old female with a BMI of 40 has an estimated 5.82
fewer years of expected life compared to an analogous female with a BMI of 25. For
a comparable change in BMI in a 40-year-old male, the expected years of life lost is
5.20. CONCLUSIONS: The BMI-mortality relation is flat around the minimum, but
especially highmortality is associated with themorbidly obese. TheMFP approach
provides a robust alternative to estimating mortality by allowing the data to deter-
mine the best fitting model. The approach is also useful in estimating the relation-
ship between the full spectrum of BMI values and other health outcomes.
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CONTENT VALIDITY OF THE MULTIPLE SCLEROSIS INTERNATIONAL QOL
(MUSIQOL) QUESTIONNAIRE IN IRAN, EGYPT, MOROCCO, SAUDI ARABIA AND
TUNISIA
Trevin A1, Salmassi L1, Auquier P2
1MAPI Institute, Lyon, France, 2Timone University Hospital, Marseille, France
OBJECTIVES: The MusiQOL questionnaire was co-developed in 15 countries to as-
sess the quality of life of patientswithMultiple Sclerosis. The objective of this study
was to test the cultural relevance of the instrument in 4 Arabic countries (Egypt,
Morocco, Saudi Arabia and Tunisia) and Iran, not involved in the initial develop-
ment, and to assess the conceptual equivalence of the translations with the UK
original used as a basis for translation.METHODS: In each country, the translation
process was conducted by a linguistic expert, using either the standard forward/
backward methodology or the adjusted process (adaptation from the Saudi Arabia
version), including cognitive interviews with 6 patients. The basis for discussion
was the concept list developed in collaborationwith the author. RESULTS: Linguis-
tic and cultural issues emerged during the translation process. First, the acronym
“MS” used throughout the original version for ”Multiple Sclerosis” was replaced by
the full name in Arabic countries for clarity, but not in Iran where the patients
preferred the abbreviation. Second, using euphemistic expressions for taboo con-
cepts such as sex life proved necessary to ensure homogenous response across all
languages without any negative connotation. Finally, leisure activities (e.g. shop-
ping, going out to amovie, gardening) described in the original had to be adapted to
the religious and social context in the target countries. CONCLUSIONS: The 5 lan-
guage versions of the MusiQol were established following a proven standardized
methodology, on the basis of a concept list worked out with the author, to allow
international data pooling and mining whilst addressing the specific challenges of
regional adaptation. The process as a whole supports the advantage of integrating
continuous and diverse international feedback on wording during the linguistic
validation process.
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OBJECTIVES: The IQWiG’s method provides a concept for the drawing of an effi-
ciency limit and its extrapolation to the assessment of the cost-benefit relation.
Here benefits are to be assessed in terms of a set of clinical endpoints. PREs might
include different issues of mortality, morbidity and health-related quality of life as
well as other important factors identified as being patient-relevant. Efficiency fron-
tiers cannot be drawn for all possible outcomes, it is important to determinewhich
factors are most relevant to patients. IQWiG allows different efficiency frontiers.
How can contradictory results be interpreted? The problemwithin the utility mea-
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surement withmore than one endpoint is the generation of a cardinal index/score.
Without the prioritization and weighting of multiple endpoints a deduction of
recommendationsmight be questionable.METHODS: A pilot study was conducted
to elicit patients’ preferences about antiviral therapy of chronic hepatitis C. For the
Discrete-Choice-Experiment (DCE), 7 attributes were selected with 3 Levels each.
Therefore an orthogonal, balanced and efficient design was used and results were
analysed with random effects logit models. RESULTS: Patients and experts priori-
tized the respective endpoints in almost the same order, but weighted them differ-
ently. Sustained-Virological-Response received the highest weight followed by fre-
quency of application (patients) or duration of therapy (experts).CONCLUSIONS:Aim
was to demonstrate how DCEs can be used to empirically determine which PREs
should be included in the efficiency frontier analysis. Further it is demonstrated
how such methods can be used to prioritize across such multiple efficiency fron-
tiers. The survey demonstrated how DCEs could be used to empirically determine
which PREs are important in antiviral treatment of chronic hepatitis C. The results
could be used for the development of innovative therapeutic schemes and new
drugs which could meet patients’ needs. For IQWiG purposes the weights of PREs
are included in the health economic evaluation.
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PERCEPTIONS ABOUT ’RAPID’ WARFARIN REVERSAL WITH FRESH FROZEN
PLASMA TO REDUCE THE INR: A NOVEL SURVEY METHODOLOGY
Petrozzino J1, Hoesche J2, Jones C2
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OBJECTIVES: To determine health care provider perceptions about timing of ’rapid’
warfarin reversal-related patient care events using novel survey methodology.
METHODS: Forty-eight adult and pediatric trauma centers were contacted to par-
ticipate in a direct-to-provider (DTP) survey. Participants were asked to provide
aggregate information about patients receiving fresh-frozen plasma (FFP) for acute
warfarin reversal. RESULTS: Nineteen to 25 health care professionals from 18 cen-
ters provided information by survey. Average perceptions of time needed to infuse
FFP under this setting (mean 4.6 hrs from time of triage; 95% CI 1.0 – 8.2 hrs) are
consistent with actual, published values. In contrast, average perceptions of time
needed for initial International Normalized Ratio (INR) normalization using FFP
(mean 5.8 hrs; 95% CI 2.8 – 8.8 hrs) underestimate actual, published values by 6 – 26
hrs. Health care providers perceived that relatively little cumulative time lapses
(1.6 hrs, on the average) for completing the first FFP infusion. There is little per-
ceived time lag between ordering and beginning the first FFP infusion (0.3 hrs, on
the average), consistent with actual, published values. There is substantial re-
ported time (an additional 3.0 hrs, on the average) needed to complete subsequent
FFP infusions, amounting to 52% of all perceived time lapsing for initial INR nor-
malization in this setting. CONCLUSIONS: DTP survey methodology appears to be
an efficient method for gathering clinical information for research purposes.
Healthcare providersmay have perceptions that are different frompublished stud-
ies, including inaccurate perceptions of the delay between the time FFP infusions
are completed and time of initial INR normalization. To our knowledge, this is the
first study to show that subsequent-to-first FFP dose infusion times account for the
majority of perceived INRnormalization time. Delays to treatment completionmay
present serious downstream consequences. Such perceptions may influence clin-
ical decision making, and warrant further analysis and investigation.
Urinary/Kidney Disorders – Clinical Outcomes Studies
PUK1
INCIDENCE AND 30-DAY MORTALITY OF COMMUNITY ACQUIRED PNEUMONIA
(CAP) IN THE MEDICARE FEE-FOR-SERVICE (FFS) POPULATION
Rubin JL1, Li S2, Yu H3, Dunning S2, Sato R3
1DaVita Clinical Research, Minneapolis, MN, USA, 2Chronic Disease Research Group,
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OBJECTIVES: To estimate CAP episode incidence and 30-day mortality rates in the
Medicare FFS population 65 years of age.METHODS: Claims data from the Medi-
care 5% sample were used to identify pneumonia diagnoses between July 1, 2007 to
June 30, 2008.We defined pneumonia hospitalizations as either Part A (PA) primary
discharge diagnosis (pdd) of pneumonia, or sepsis or respiratory failure as pdd plus
pneumonia as secondary diagnosis. Outpatient pneumonia was defined as a pneu-
monia diagnosis from PA outpatient or non-hospital sourced Part B, with claim for
chest x-ray within 14 days of pneumonia diagnosis. CAP episodes were defined as
being indexed on the first pneumonia claim date followed through the last pneu-
monia claim date preceded and followed by a 90 day clean period, respectively.
Episodes were defined as outpatient, unless beginning with or containing a CAP
hospitalization, in which case they were considered inpatient CAP episodes. We
further excluded evidence of hospitalization, long-term care and mechanical ven-
tilator use from claims within 14 days of the CAP index date. Incidence and mor-
tality were stratified by inpatient status and age. RESULTS: A total of 56,262 CAP
episodes were identified; 38.4% were inpatient. The average inpatient and outpa-
tient episode length was 32.7 days (SD 46.3) and 12.8 days (SD 27.6), respectively.
Corresponding incidence rates were 1,767/100,000 person-years for inpatient and
2,837/100,000 for outpatient CAP. Overall incidence rises with increasing age, rang-
ing from 2,786/100,000 person-years for those 65-69 to 8,449/100,000 for those 85.
Overall 30-day case-fatality was 5.6%; 8.5% for inpatient and 3.8% for outpatient
CAP. Case-fatality rates also increase with increasing age. CONCLUSIONS: The
overall incidence of CAP in the Medicare FFS population of 4,604/100,000 person-
years is substantial. These results suggest an estimated 1.13 million cases of CAP
and 63,000 CAP-related deaths annually among this population. CAP remains an
important public health burden in the United States.
PUK2
DUTASTERIDE FOR BENIGN PROSTATIC HYPERPLASIA: A SYSTEMATIC REVIEW
AND META-ANALYSIS
Park T, Shamliyan TA
University of Minnesota, Minneapolis, MN, USA
OBJECTIVES: This study systematically reviews existing evidence to determine the
efficacy and adverse events of dutasteride, alone or in combination, versus a pla-
cebo or control, used for the treatment of benign prostatic hyperplasia (BPH).
METHODS:Medline and the Cochrane Library were searched for randomized con-
trolled trials that were longer than six months in duration. The study population
was men, aged 50 or older, with moderate and severe symptoms of BPH as deter-
mined by the International Prostate Symptom Score (IPSS) and clinical parameters
includingmaximumurinary flow rate (Qmax) and prostate volume. Ameta-analysis
with a random effects model was conducted to synthesize the findings of multiple
studies. Heterogeneity among the studies was assessed both graphically with for-
est plots and statistically with I2 statistics. RESULTS: Dutasteride was superior to
the placebo in reducing urinary symptoms measured by IPSS [weighted mean dif-
ference (WMD)  2.50, 95% confidence intervals (CIs)  2.91 to 2.09], prostate
volume (WMD12.90, 95% CIs14.27 to11.53) and in increasing Qmax (WMD
1.30, 95% CIs  0.99 to 1.61). However, risk ratios for any adverse events (1.27, 95%
CIs  0.99 to 1.62) and for drug-related adverse events (1.47, 95% CIs  0.77 to 2.79)
were not significantly different between those treated with dutasteride and those
in the control group. When dutasteride was administered with tamsulosin, the
reduction in IPSS scores and the increase in Qmax were greater than if the medica-
tions were administered alone, although prostate volume changed little. For both
BPH-related acute urinary retention (AUR) and BPH-related surgery, no significant
difference in risk ratio was observed between the combination group and the du-
tasteride group. CONCLUSIONS: Dutasteride can be used for those with moderate
to severe BPH symptoms when benefits from efficacy are considered to be greater
than the loss from adverse events.
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DRUG-INDUCED ACUTE RENAL FAILURE USING THE FDA ADVERSE EVENT
REPORTING SYSTEM DATABASE
Alhammad AM, Al Hawaj MA, Alsalman AJ, Alhashem YN, Harpe SE, Smith WR,
Brophy DF
Virginia Commonwealth University, Richmond, VA, USA
OBJECTIVES: The incidence of acute renal failure (ARF) is increasing. A substantial
proportion of these cases are due to drug-induced nephrotoxicity. Data from post-
marketing surveillance programs, like the FDA Adverse Event Reporting System
(AERS), can be useful in assessing the risk of adverse drug events. Our objective is to
describe reports with ARF (cases) and reports without ARF (non-cases) and out-
comes resulting from ARF using the AERS database. METHODS: Data were ex-
tracted from the AERS database from 2004–2009. All reports of cases and non-cases
were described and analyzed in term of suspected drugs, health outcomes, and
other characteristics. Descriptive statistics (frequencies and proportions) and Chi-
square tests were used. RESULTS: The AERS data used in this study represents
2,231,689 reports from 184 countries with 27,190 involving reports of ARF (cases).
There was approximately a two-fold increase in the percentage of reports of ARF
from 2004 to 2009 (n 3,594; 13% to n 6,104; 22%, respectively). Most reports were
submitted by manufacturers (cases  89%, non-cases 93%). The majority of re-
ports were for infants (cases  75%, non-cases  57%). In cases, drugs were the
primary suspect, the secondary suspect and concomitant in 18%, 14% and 66% of
reports, respectively. The five drugs with the highest reported frequencies of ARF
were rofecoxib, valacyclovir, metformin, simvastatin, and digoxin. Unfavorable
outcomesweremore likely to occur in cases than non-cases (death 24% vs. 12%, life
threatening condition 21% vs. 5%, initial/prolonged hospitalization 76% vs. 33%,
disability 6% vs. 4% and required intervention 4% vs. 2%; p-value  0.001, for all
comparisons). CONCLUSIONS: These preliminary findings present an overall pic-
ture of reports with ARF. These findings can be informative for regulatory author-
ities and healthcare professionals. Additional analyses with reporting odd ratios
(ROR) are needed to support these initial findings.
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CUMULATIVE EXPOSURE TO NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
(NSAIDS) AND THE PROGRESSION OF CHRONIC KIDNEY DISEASE (CKD)
Yarger S1, Nwokeji E1, Trice S2, Chao S3, Devine J2, Potyk R2, Gutke G4, Bonnema A3
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OBJECTIVES: To examine the relationship between NSAID use and the progression
of CKD for a cohort of elderly patients within the military health system.
METHODS:All patients with at least one serum creatininemeasurement in each of
the time periods July 1–December 31, 2006 and July 1–December 31, 2008 with a
baseline estimated glomerular filtration rate (eGFR) representing CKD stage 2 or 3,
whowere 67 years of age, continuously eligible for TRICARE, and received care at
a military treatment facility were included in a retrospective database analysis.
Logistic regression analyses were used to explore associations between NSAID use
and rapid progression of CKDdefined as a decrease in eGFR of 15mL/min/1.73m2.
Covariates included age, gender, diabetes, hyperlipidemia, hypertension, and
NSAID exposure level. RESULTS: A total of 34,295 patients (median age 73.5, 50.2%
male) met the inclusion/exclusion criteria. A total of 14,576 patients had some
NSAID use, while 19,719 had no NSAID use. Rapid CKD progression occurred for
10.5% of no useNSAID patients (2,063 of 19,720), 11.2% of low tomediumNSAID use
patients (1,465 of 13,125), and 13.4% of high NSAID use patients (195 of 1,450).
Logistic regression results showed that stage 2-3 CKD patients with low tomedium
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